Skip to content

BEPHARMA

Inactive
KBO/BCE: BE 0455.037.193

Inactive; last annual accounts for financial year 2025.

BEPHARMAInactive

Overview

Activity
“De vennootschap heeft als voorwerp:- Het overnemen,oprichting en uitbating van apotheken,aankoop en verkoop,in- en…” (deed in Dutch)
From the articles, 8 activitiesNo NACE code in the KBO yet
Size
€1.2mtotal assets 2025
Equity
€942,099
Profit
€93,560
Turnover not published (abbreviated format)Net result -60%: 5-month year
Financial health
Inactive: no score
Structure
6 of 7 deeds summarised
SignalsneutralLatest accounts filed on timeShow the evidence

Signals

1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 28-05-2025 was due by 28-12-2025 and was filed on 10-07-2025, 171 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
171 days early
2024
34 days early
2023
65 days early
2022
62 days early
2021
74 days early
2020
68 days early
2019
65 days early
← before the deadline after the deadline →
tick = median of all Belgian filings

This company filed its last 7 accounts on average 77 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.

Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · abbreviated…
  3. Restructuring · End & cessationMerger · Accounting effect

Financials · financial year 2025, abbreviated format

Equity
€942,099▲ 11.0%
2024 · €848,539
Total assets
€1.2m▲ 3.8%
2024 · €1.2m
Net result
€93,560▼ 60.4%
2024 · €236,325
Working capital
€821,629▲ 1.3%
2024 · €811,016
Trend over the years

2021 to 2025, 5 financial years 2018 to 2025, 8 financial years

The operating result falls in 2025; 2025 is 54% below 2024 and is the lowest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result€0.1m 2025 Net result€0.09m 2025

Use the arrow keys on the chart for the figures per year.

Every figure with its change against the financial year before
favourable unfavourable
Line20182019202020212022202320242025
Operating result€0.08m-€0.1m▲ 66.4%€0.1m▲ 4.6%€0.1m▼ 6.5%€0.2m▲ 58.0%€0.2m▼ 16.6%€0.3m▲ 52.7%€0.1m▼ 53.6%
Net result-€0.004m-€0.05m€0.06m▲ 21.3%€0.05m▼ 17.5%€0.1m▲ 120%€0.09m▼ 21.9%€0.2m▲ 167%€0.09m▼ 60.4%
Equity€0.2m-€0.3m▲ 21.1%€0.4m▲ 21.2%€0.4m▲ 14.4%€0.5m▲ 27.7%€0.6m▲ 16.9%€0.8m▲ 38.6%€0.9m▲ 11.0%
Total assets€1.2m-€1.1m▼ 8.0%€1.1m▲ 0.5%€1.1m▲ 1.3%€1.1m▲ 0.3%€1.0m▼ 10.6%€1.2m▲ 19.9%€1.2m▲ 3.8%
Debt€0.9m-€0.8m▼ 15.8%€0.7m▼ 7.5%€0.7m▼ 5.4%€0.6m▼ 16.3%€0.4m▼ 36.2%€0.3m▼ 12.0%€0.3m▼ 15.4%
Working capital€0.3m-€0.4m▲ 23.1%€0.5m▲ 21.7%€0.6m▲ 9.6%€0.7m▲ 19.1%€0.6m▼ 9.8%€0.8m▲ 32.3%€0.8m▲ 1.3%
Staff (FTE)5.1-4.1▼ 19.6%4.3▲ 4.9%5.1▲ 18.6%4.6▼ 9.8%4.5▼ 2.2%3.3▼ 26.7%
Turnover and EBIT margin not published: the abbreviated format does not require them.
Why a figure moved sharply
  • 2025 Net result -60% on 2024. This financial year ran 5 months, the previous one 12.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.2m
Fixed assets €120,470 ▼ 6.0%
Current assets €1.1m ▲ 5.1%
Equity and liabilities €1.2m
Equity €942,099 ▲ 11.0%
Debt €268,212 ▼ 15.4%
Debt's share of the balance-sheet total falls from 27.2% to 22.2%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€124,482▼
2024 · €274,633
Cash flow
€101,282▼
2024 · €259,064
Current ratio
4.06▼
2024 · 4.58
Quick ratio
3.63▼
2024 · 4.02
Debt to equity
0.28▼
2024 · 0.37
ROE
9.9%▼
2024 · 27.9%
ROA
7.7%▼
2024 · 20.3%
Interest coverage
25.26▼
2024 · 28.75
Debt ≤ 1 year
€268,212▲
2024 · €226,252
Income taxes
€28,367▼
2024 · €54,604
Staff costs
€107,211▼
2024 · €241,300
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 53 lines
Balance sheet Code20242025
Assets
Total assets20/58€1.2m€1.2m▲
Fixed assets21/28€0.1m€0.1m▼
Tangible fixed assets22/27€0.1m€0.1m▼
Land and buildings22€0.1m€0.1m▼
Plant, machinery and equipment23€0.02m€0.01m▼
Current assets29/58€1.0m€1.1m▲
Stocks and contracts in progress3€0.1m€0.1m▼
Stocks30/36€0.1m€0.1m▼
Amounts receivable within one year40/41€0.7m€0.9m▲
Trade receivables40€0.06m€0.06m▼
Other amounts receivable41€0.6m€0.8m▲
Current investments50/53€0.003m-
Cash at bank and in hand54/58€0.2m€0.08m▼
Deferred charges and accrued income490/1€0.01m-
Equity and liabilities
Total equity and liabilities10/49€1.2m€1.2m▲
Equity10/15€0.8m€0.9m▲
Contributions10/11€0.03m€0.03m=
Reserves13€0.3m€0.3m=
Non-distributable reserves130/1€0.003m€0.003m=
Reserves not available under the articles1311€0.003m€0.003m=
Distributable reserves133€0.3m€0.3m=
Profit (loss) carried forward14€0.5m€0.6m▲
Amounts payable17/49€0.3m€0.3m▼
Amounts payable after more than one year17€0.08m-
Financial debts170/4€0.08m-
Amounts payable within one year42/48€0.2m€0.3m▲
Current portion of amounts payable after more than one year42€0.07m-
Trade debts44€0.04m€0.04m▼
Suppliers440/4€0.04m€0.04m▼
Taxes, remuneration and social security45€0.09m€0.1m▲
Taxes450/3€0.06m€0.08m▲
Remuneration and social security454/9€0.03m€0.03m▼
Other amounts payable47/48€0.02m€0.1m▲
Accrued charges and deferred income492/3€0.01m-
Income statement Code20242025
Non-recurring operating income76A€0€0.001m▲
Remuneration, social security and pensions62€0.2m€0.1m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.02m€0.008m▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.005m-
Other operating charges640/8€0.003m€0.003m▼
Non-recurring operating charges66A€21€12▼
Gross operating margin9900€0.5m€0.2m▼
Operating profit (loss)9901€0.3m€0.1m▼
Financial income75/76B€0.05m€0.01m▼
Recurring financial income75€0.05m€0.01m▼
Financial charges65/66B€0.01m€0.005m▼
Recurring financial charges65€0.01m€0.005m▼
Profit (loss) for the period before taxes9903€0.3m€0.1m▼
Income taxes67/77€0.05m€0.03m▼
Profit (loss) for the period9904€0.2m€0.09m▼
Profit (loss) for the period to be appropriated9905€0.2m€0.09m▼
Appropriation of the result
Profit (loss) to be appropriated9906€0.5m€0.6m▲
Profit (loss) brought forward from the previous period14P€0.3m€0.5m▲
Social balance sheet
Average headcount (FTE)90873.3-

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20182019202020212022202320242025Change
Non-recurring operating income76A------€0€691▲ 17,280×
Remuneration, social security and pensions62---€218,198€207,952€238,541€241,300€107,211▼ 55.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€116,464€96,896€94,435€80,695€77,187€57,308€22,739€7,721▼ 66.0%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4------€4,611--
Other operating charges640/8---€1,319€1,014€638€2,824€2,801▼ 0.8%
Non-recurring operating charges66A------€21€12▼ 41.9%
Gross operating margin9900€389,282€441,167€434,731€425,352€483,914€461,415€523,389€234,505▼ 55.2%
Operating profit (loss)9901€76,910€127,946€133,856€125,140€197,762€164,928€251,894€116,760▼ 53.6%
Financial income75/76B---€578€2,310€2,205€48,586€10,096▼ 79.2%
Recurring financial income75€1,404€76€11,477€578€2,310€2,205€48,586€10,096▼ 79.2%
Financial charges65/66B---€47,437€47,649€45,491€9,552€4,929▼ 48.4%
Recurring financial charges65€84,764€51,658€51,240€47,437€47,649€45,491€9,552€4,929▼ 48.4%
Profit (loss) for the period before taxes9903€9,373€76,364€94,093€78,281€152,423€121,642€290,929€121,927▼ 58.1%
Income taxes67/77€13,045€24,750€31,479€26,604€38,932€32,993€54,604€28,367▼ 48.0%
Profit (loss) for the period9904-€3,671€51,614€62,613€51,677€113,491€88,649€236,325€93,560▼ 60.4%
Profit (loss) for the period to be appropriated9905-€3,671€51,614€62,613€51,677€113,491€88,649€236,325€93,560▼ 60.4%
Line20182019202020212022202320242025Change
Assets
Total assets20/58€1.2m€1.1m€1.1m€1.1m€1.1m€1.0m€1.2m€1.2m▲ 3.8%
Fixed assets21/28€0.5m€0.4m€0.3m€0.3m€0.2m€0.2m€0.1m€0.1m▼ 6.0%
Tangible fixed assets22/27€0.5m€0.4m€0.3m€0.3m€0.2m€0.2m€0.1m€0.1m▼ 6.0%
Land and buildings22---€0.2m€0.2m€0.1m€0.1m€0.1m▼ 4.9%
Plant, machinery and equipment23---€0.02m€0.03m€0.02m€0.02m€0.01m▼ 14.5%
Furniture and vehicles24---€0.005m€0.003m€0.002m---
Financial fixed assets28€124€124€124€124€124----
Current assets29/58€0.7m€0.7m€0.8m€0.8m€0.9m€0.8m€1.0m€1.1m▲ 5.1%
Stocks and contracts in progress3€0.2m€0.2m€0.2m€0.2m€0.2m€0.2m€0.1m€0.1m▼ 10.4%
Stocks30/36---€0.2m€0.2m€0.2m€0.1m€0.1m▼ 10.4%
Amounts receivable within one year40/41€0.2m€0.3m€0.3m€0.2m€0.2m€0.2m€0.7m€0.9m▲ 32.1%
Trade receivables40---€0.2m€0.2m€0.2m€0.06m€0.06m▼ 4.6%
Other amounts receivable41---€0.004m€0.004m€0.004m€0.6m€0.8m▲ 35.8%
Current investments50/53€0.1m€0.1m€0.1m€0.2m€0.2m€0.3m€0.003m--
Cash at bank and in hand54/58€0.1m€0.1m€0.2m€0.2m€0.2m€0.1m€0.2m€0.08m▼ 62.1%
Deferred charges and accrued income490/1---€0.03m€0.03m€0.03m€0.01m--
Equity and liabilities
Total equity and liabilities10/49€1.2m€1.1m€1.1m€1.1m€1.1m€1.0m€1.2m€1.2m▲ 3.8%
Equity10/15€0.2m€0.3m€0.4m€0.4m€0.5m€0.6m€0.8m€0.9m▲ 11.0%
Contributions10/11€0.03m€0.03m-€0.03m€0.03m€0.03m€0.03m€0.03m=
Reserves13€0.1m€0.2m€0.2m€0.3m€0.3m€0.3m€0.3m€0.3m=
Non-distributable reserves130/1---€0.003m€0.003m€0.003m€0.003m€0.003m=
Reserves not available under the articles1311---€0.003m€0.003m€0.003m€0.003m€0.003m=
Distributable reserves133---€0.3m€0.3m€0.3m€0.3m€0.3m=
Profit (loss) carried forward14€0.1m€0.1m€0.1m€0.1m€0.2m€0.3m€0.5m€0.6m▲ 17.0%
Amounts payable17/49€0.9m€0.8m€0.7m€0.7m€0.6m€0.4m€0.3m€0.3m▼ 15.4%
Amounts payable after more than one year17€0.6m€0.5m€0.5m€0.4m€0.4m€0.2m€0.08m--
Financial debts170/4---€0.4m€0.4m€0.2m€0.08m--
Amounts payable within one year42/48€0.3m€0.2m€0.2m€0.2m€0.2m€0.2m€0.2m€0.3m▲ 18.5%
Current portion of amounts payable after more than one year42---€0.08m€0.07m€0.06m€0.07m--
Trade debts44€0.1m€0.1m€0.1m€0.1m€0.09m€0.1m€0.04m€0.04m▼ 17.5%
Suppliers440/4---€0.1m€0.09m€0.1m€0.04m€0.04m▼ 17.5%
Taxes, remuneration and social security45---€0.04m€0.04m€0.05m€0.09m€0.1m▲ 12.9%
Taxes450/3---€0.02m€0.01m€0.02m€0.06m€0.08m▲ 20.7%
Remuneration and social security454/9---€0.03m€0.02m€0.03m€0.03m€0.03m▼ 3.5%
Other amounts payable47/48---€0.02m€0.01m€0.001m€0.02m€0.1m▲ 478%
Accrued charges and deferred income492/3---€0.001m€427-€0.01m--
Line20182019202020212022202320242025Change
Profit (loss) for the period9904-€3,671€51,614€62,613€51,677€113,491€88,649€236,325€93,560▼ 60.4%
+ Depreciation and write-downs630€116,464€96,896€94,435€80,695€77,187€57,308€22,739€7,721▼ 66.0%
Operating cash flow (approximation)€112,793€148,510€157,049€132,372€190,678€145,957€259,064€101,282▼ 60.9%
Investment in fixed assets (approximation)--€13,415-€7,160-€40,758-€15,817-€2,254€0€0-
Change in cash-€925€61,283€46,012-€18,565-€88,451€93,312-€136,846-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 31 filings with the National Bank
Financial year Type Filed Reference
28-05-2025 abbreviated format 10-07-2025 2025-00276369
31-12-2024 abbreviated format 27-06-2025 2025-00211221
31-12-2023 abbreviated format 27-05-2024 2024-00101759
31-12-2022 abbreviated format 30-05-2023 2023-00104920
31-12-2021 abbreviated format 18-05-2022 2022-20032268
31-12-2020 abbreviated format 24-05-2021 2021-15100573
31-12-2019 abbreviated format 27-05-2020 2020-13500192
31-12-2018 abbreviated format 02-07-2019 2019-28800491
31-12-2017 abbreviated format 31-08-2018 2018-59100102
31-12-2016 abbreviated format 25-07-2017 2017-34700126

Show all 31 filings

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
2 directors, last change in 2024
An Marin
Director · since 02-09-2024
Current
Arnaud Berken
Director · since 02-09-2024
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
1 of this company's 7 Belgian Official Gazette deeds has not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.

Mandate history

3 people since 2023, 2 in office
Show
  • Board
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
An Marin
  • Director, from 02-09-2024 to date
Arnaud Berken
  • Director, from 02-09-2024 to date
BECKERS Bartje Marie-Françoise Wilfried
  • Enige statutaire bestuurder (zaakvoerder), until 28-08-2023
  • Statutory director, from 28-08-2023 to 27-09-2024
See the board, name and registered office on a given date →

Owners and capital

Owners

Owners 0

No owner stated in the accounts, acts or LEI register we read.

Stated earlier (1)

An older source named these owners; newer accounts no longer list them.

Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Capital and shareholders

Shareholders according to the deeds
Stated in the act act of 17-04-2025 ↗
  • BENU Management NV all shares
Stated in the act act of 20-03-2025 ↗
  • BENU Management NV all shares
Stated in the act act of 03-10-2024 ↗
Share transfer act of 03-10-2024 ↗

The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 05-09-2023 Converted to unavailable equity · €35,750

Group and network

Connections & network

2 connected companies
Depth

The connected companies are in the list below.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Bephacon
Shared director
→
WIJMENPUT
Shared director
→

Acquisitions and mergers

1 transaction
Taken over by:BENU
BE 0436.826.929operation treated as a merger by absorption · Gazette deed of 24-06-2025 (9 acts) · effective 01-06-2025

History

The board currently has 2 members; 2 of them have served since 2024.1 BEPHARMA has filed 31 sets of annual accounts, the latest for financial year 2025.2 In 2025 the company was absorbed by merger into BENU.3

  1. 1Belgian Official Gazette, 27-09-2024
  2. 2National Bank, annual accounts 2025
  3. 3Belgian Official Gazette, 24-06-2025

Acts, filings and financial milestones

2025
10-07
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
27-06
NBB filing Annual accounts filed
financial year 2024 · abbreviated format
24-06
Gazette deed Restructuring · End & cessation
Merger · Accounting effect5 facts ▸
  • General meeting, 28-05-2025
  • Other provision, “kennisname fusievoorstel, EERSTE BESLISSING” (deed in Dutch)
  • Merger, “verrichting gelijkgesteld met fusie door overneming, goedkeuring fusievoorstel” (deed in Dutch)
  • Accounting effect, 01-06-2025
  • Other provision, “uitreiking vóór registratie, artikel 173, 1°bis Wetboek van registratierechten” (deed in Dutch)
17-04
Gazette deed Miscellaneous
Merger · Shareholding · Accounting effect14 facts ▸
  • Merger, “geruisloze fusie, artikel 12:50 van het Wetboek van vennootschappen en verenigingen” (deed in Dutch)
  • Shareholding, “buitengewone algemene vergaderingen ter goedkeuring voorgestelde fusie” (deed in Dutch) (2 times)
  • Accounting effect, 01-06-2025 (2 times)
  • Registered office clause, “Avenue Pasteur 2,1300 Waver” (deed in Dutch)
  • Registered office clause, “Grote Baan 201, 9310 Aalst” (deed in Dutch)
  • Other provision, “voorwerp overnemende vennootschap” (deed in Dutch)
  • Other provision, “bijzondere voordelen bestuursorganen, artikel 12:50, lid 2, 4° WVV” (deed in Dutch)
  • Other provision, “rechten aandeelhouders met bijzondere rechten en houders andere effecten, artikel 12:50, lid 2, 3° WVV” (deed in Dutch)
  • Real estate, “lot 2, 3a 92ca” (deed in Dutch)
  • Other provision, “bodemsanering overdracht, artikel 2,18° decreet 27-10-2006 bodemsanering en bodembescherming” (deed in Dutch)
  • Other provision, “bodemattest, https://www.vlaanderen.be/pfas-vervuiling” (deed in Dutch)
  • Other provision, “kennis bodemattest, voordat de fusie werd voltooid” (deed in Dutch)
  • +2 further facts in this act
20-03
Gazette deed Miscellaneous
Merger · Capital increase · Incorporation15 facts ▸
  • Merger, “fusie door overneming, gehele vermogen,zowel rechten als verplichtingen” (deed in Dutch)
  • Other provision, “structuur vereenvoudigen en aantal juridische entiteiten verminderen, synergieën tot stand brengen,alsmede integratie van personeel” (deed in Dutch)
  • Capital increase
  • Incorporation, 27-04-1995
  • Incorporation, 08-02-1989
  • Share issue, 14855, “raad van bestuur van BENU NV” (deed in Dutch)
  • Other provision, “opleg in geld”, 0 (deed in Dutch)
  • Shareholding, BENU Management NV
  • Accounting effect, “juridisch,boekhoudkundig en fiscaal, datum van de buitengewone algemene vergadering die de fusie zal goedkeuren” (deed in Dutch)
  • Other provision, “bijzondere rechten” (deed in Dutch)
  • Other provision, “bijzondere voordelen bestuurders” (deed in Dutch)
  • Amendment of the articles
  • +3 further facts in this act
2024
31-12
Financial Highest result from 2018 to 2025net €236,325 ▲167%
Operating result €251,894, net result €236,325, both a record.
03-10
Gazette deed Capital & shares
Share transfer · Shareholding4 facts ▸
  • Share transfer, BENU Managament SA
  • Shareholding, 12-09-2024
  • Board meeting, 12-09-2024
  • Other provision, “vereniging van alle aandelen in één hand met toepassing van artikel 2:8, §4 WVV, artikel 2:8, §4 van het Wetboek van vennootschappen en verenigingen” (deed in Dutch)
27-09
Gazette deed Resignation: Bartje Beckers (statutory director)
Appointments: Arnaud Berken (director) and An Marin (director)6 facts ▸
  • General meeting, 02-09-2024
  • Director resignation, Bartje Beckers (statutory director)
  • Other provision, “kwijting ontslagnemend bestuurder, vanaf het begin van het lopende boekjaar” (deed in Dutch)
  • Other provision, “notariële bevestiging ontslag en statutenwijziging, zo snel als mogelijk per notariële akte” (deed in Dutch)
  • Director appointment, Arnaud Berken (director)
  • Director appointment, An Marin (director)
27-05
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
2023
05-09
Gazette deed Resignation: BECKERS Bartje Marie-Françoise Wilfried (enige statutaire bestuurder)
Appointment: BECKERS Bartje Marie-Françoise Wilfried (statutory director) · Legal-form conversion · Capital conversion12 facts ▸
  • Board composition, BECKERS Bartje Marie-Françoise Wilfried (statutory director)
  • General meeting, 28-08-2023
  • Legal-form conversion, “besloten vennootschap” (deed in Dutch)
  • Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
  • Director resignation, BECKERS Bartje Marie-Françoise Wilfried (enige statutaire bestuurder (zaakvoerder))
  • Director discharge, BECKERS Bartje Marie-Françoise Wilfried
  • Director appointment, BECKERS Bartje Marie-Françoise Wilfried (statutory director)
  • Other provision, “vrijstelling voorlezing bestuursorgaanverslag”, 28-08-2023 (deed in Dutch)
  • Other provision, “goedkeuring verslag bestuursorgaan” (deed in Dutch)
  • Purpose change
  • Amendment of the articles
  • Capital
30-05
NBB filing Annual accounts filed
financial year 2022 · abbreviated format
2022
31-12
Financial Equity above €500,000equity €523,565 ▲27.7%
4 profitable years in a row build equity to €523,565.
Show earlier events
18-05
NBB filing Annual accounts filed
financial year 2021 · abbreviated format
2021
24-05
NBB filing Annual accounts filed
financial year 2020 · abbreviated format
2020
27-05
NBB filing Annual accounts filed
financial year 2019 · abbreviated format
2019
31-12
Financial Back to profitnet €51,614
Net result €51,614 after one loss-making year.
02-07
NBB filing Annual accounts filed
financial year 2018 · abbreviated format
2018
31-08
NBB filing Annual accounts filed
financial year 2017 · abbreviated format · 31 days late
2017
25-07
NBB filing Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 31 annual accounts filed, the latest 10 are here; all 31 are under Financials.
6 of 7 deeds read
About the unread acts

Of the 7 Belgian Official Gazette deeds we know for this company, 6 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Articles of association

What the company does

PurposeThe activities the company may carry out under its articles.
“De vennootschap heeft als voorwerp:- Het overnemen,oprichting en uitbating van apotheken,aankoop en verkoop,in- en uitvoer,fabricatie in het…” (deed in Dutch)
8 activities (deed in Dutch)
  1. De vennootschap heeft als voorwerp:- Het overnemen,oprichting en uitbating van apotheken,aankoop en verkoop,in- en uitvoer,fabricatie in het groot en in het klein,van scheikundige,farmaceutische en parafarmaceutische producten en artikelen.
  2. De handel in kruiden,drogisterij,parfumerie,schoonheidstoilet,verband-,dieet-,laboratorium-,optische- en onderhoudsartikelen en aanverwante producten of diensten;
  3. Het ondernemen van industriële en klinische ontledingen
  4. Iedere handelsbedrijvigheid welke met de gezondheidszorg verband houdt en dit in de meest uitgebreide zin
  5. Het vervaardigen,destilleren,aan- en verkopen,groot- en kleinhandel,import en export van alle soorten alcoholische dranken,zowel fysiek in één of meerdere winkels als via webshop.
  6. Verder is de vennootschap gerechtigd zowel in België als in het buitenland,alle industriële,handels-,financiële,roerende en onroerende handelingen te verrichten die in verband kunnen gebracht worden met wat hierboven niet limitatief werd opgesomd,met inbegrip van alle verrichtingen in verband met merken,brevetten en andere onlichamelijke rechten.
  7. Zij mag daarenboven rechtstreeks of onrechtstreeks deelnemen aan de werking van andere vennootschappen,bedrijven of groeperingen met eenzelfde,een gelijkaardig of aanverwant voorwerp of van wie het voorwerp van aard is dat van de vennootschap te bevorderen.
  8. Zij mag zich voor deze vennootschappen borg stellen en aval verlenen,voorschotten en kredieten toestaan en hypothecaire of andere waarborgen verstrekken.

The full purpose is in the deed

deed of 17-04-2025
DurationHow long the company exists; usually unlimited, so until it is dissolved.
Unlimited
deed of 05-09-2023
Name clauseThe name the company operates under according to its articles.
BEPHARMA
deed of 05-09-2023
Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
“Vlaams Gewest, voor zover geen wijziging taalregime” (deed in Dutch)
deed of 05-09-2023

Who represents it, and how

Board ruleHow the board is made up, meets and takes decisions.
“Met of zonder beperking, natuurlijke personen of rechtspersonen al dan niet aandeelhouder” (deed in Dutch)
1 more provision on this in the deed

deed of 05-09-2023

Capital, shares and profit

Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
“Helft overdrager helft koper(s) naar evenredigheid aantal verworven aandelen, elke overdracht onder levenden ten bezwarende of kosteloze…” (deed in Dutch)
Share issue ruleHow and by whom new shares can be issued.
“Dag van openstelling van de intekening, overblijvende aandelen eerst aan aandeelhouders die voorkeurrecht volledig uitoefenden tot volledig…” (deed in Dutch)

deed of 05-09-2023

Meetings and financial year

Financial yearThe twelve-month period the company draws up its annual accounts for.
From 1 January to 31 December
Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
Last Friday of June at 19:00

deed of 05-09-2023

Oversight and winding up

Dissolution ruleWhen and by whom the company can be dissolved.
“Vormen vereist voor statutenwijziging, op elk moment” (deed in Dutch)
“Besluit algemene vergadering beraadslagend zoals inzake statutenwijziging” (deed in Dutch)
Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
“Vereffenaars, om welke reden en op welk ogenblik ook” (deed in Dutch)

deed of 05-09-2023

Other provisionsOther rules from the articles that fall under none of the themes above.

Other provision: “Waarborgen voor andere vennootschappen” (deed in Dutch)
deed of 17-04-2025
1 more provision in the deed, see the deed of 05-09-2023